VCU Stravitz-Sanyal Institute for Liver Disease
@VCU_Liver
Followers
696
Following
1K
Media
465
Statuses
2K
The Stravitz-Sanyal Institute for Liver Disease and Metabolic Health at VCU is revolutionizing global health through innovative liver research. 804-828-5066.
Richmond, VA
Joined April 2023
World Health Organization #WHO guideline on the use of GLP-1 medications in obesity. https://t.co/mslI6X4Fbx
2
29
114
Final few days to submit your abstract to #DDW2026! Submission window closes at 21:00 Eastern time (UTC –5 on 12/4. Learn more:
Discoveries await at #DDW2026 — lead the way with your research. Submit your abstract by Dec. 4 at https://t.co/jg2RuXBv8O .
0
2
3
Team #VCU!
Check out our review on novel biomarkers for 🍷liver disease in @CMH_journal From ELF, Pro-C3 & CK-18 to genetics, microbiome & multi-omics 🧬 Practical visuals for busy clinicians included 🩺 ✨ team @juanpabloarab @MarcoArreseMD @LuisAntonioDiaz @BlaneyMD @FcoIdalsoaga
0
1
7
In @gastroendonews this month, w/lead investigator our @jasmohanbajaj: Machine Learning Cirrhosis Mortality Prediction. #livertwitter #gastroendonews
https://t.co/hVJPcTKjzJ
0
1
1
From @RichSterlingMD: New score challenges old predictors. "MERAGE has superior performance for predicting return to drinking (RTD) compared to HRAR in AH." https://t.co/We2FS7ZpmI
#livertwitter #liver #liverhealth
conexiant.com
0
0
0
What wonderful news, #kritisoni50! Way to go! #livertwitter
Thrilled to share that I was featured with a VCU Starburst Award! It’s an honor to be part of the incredible team @ASRG_Liver @VCU_Liver. Thank you to my mentor for constant support @juanpabloarab .Looking forward to continuing meaningful work. @VCUHealth @VCUInternalMed
1
0
2
📢Anyone caring for patients with alcohol-associated liver disease! This one-pager summarizes the @AASLDtweets guideline on ALD. It is a must-have for all residents, hospitalists, and GI Fellows! @LiverFellow @geneyim #MedEd
🧭 Guidelines Corner 🍷 Alcohol-Associated Liver Disease affects millions each year, but what do the newest #AASLD guidelines actually recommend? @ElinaStoffel breaks it down in a crisp, high-yield summary ✨ 🔖Read it here ➡️ https://t.co/PmWoh5K8D9 DOI: 10.1002/hep.30866
3
32
84
Thanks to AJMC for covering this research on using NITs to track treatment response in semaglutide #MASH trial. #livertwitter
https://t.co/dSzUVmreqd
ajmc.com
A wide range of non-invasive tests reliably reflected semaglutide-related improvements in metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis.
0
1
4
🪦Pentoxifylline. While many of us thought pentoxifylline 🪦 in 2014, it is still used in AH in many parts of the world (likely given the lack of effective pharmacotherapy). This excellent study again shows that: 🔨Pentoxifylline has no role in the treatment of AH.
Pentoxifylline for severe alcohol-associated hepatitis with AKI? No survival benefit ‼️ in a multinational real-world cohort. Let’s retire reflex use and invest in better therapies!! 🆙 #EvidenceMatters #LiverTwitter #ASRG_Liver
0
6
14
Don’t miss out on the next @alehlatam @AASLDtweets webinar: Hot Topics in ALD and MetALD. Coordinated by @juanpabloarab We will have excellent speakers @FATIMAHiguera8 @BlaneyMD @geneyim and live translation! 🔗Registration link: https://t.co/ZpAnZNoX67
1
11
31
.@HEP_Journal introduces incoming AASLD president @saulkarpen, our chief scientific officer. He is the 5th pediatrician in the Society’s 70+ year history to become president. Learn about his journey in pediatric hepatology. https://t.co/z9A9ujkntK
#livertwitter #aasldtweets
3
5
26
Can we use NLP #AI to ⬆️objectivity of #Hepaticencephalopathy diagnosis? Yes! 3 cohorts (@RichmondVAMC @VCU_Liver #NACSELD) showed 5 phrases w ⬆️value Implications for 🔑 #Transplant priority 🔑 remote adjudication of clinical trials https://t.co/EmXhJ5GFqD
@AmJGastro
1
13
42
Join us for our next research seminar on Nov. 19 at noon. Our @ObiAseemMDPhD will speak on "Transcriptomic and Lipidomic Regulation of Cholangiocyte Fibroinflammatory Signaling in Biliary Fibrosis." Register at https://t.co/NuUgnx8KUH
0
0
1
Join us for our next research seminar on Nov. 19 at noon. Our @ObiAseemMDPhD will speak on "Transcriptomic and Lipidomic Regulation of Cholangiocyte Fibroinflammatory Signaling in Biliary Fibrosis." Register at https://t.co/NuUgnx8KUH
0
0
4
Be sure to catch @juanpabloarab Wednesday in a Keynote webinar | Spotlight on addressing alcohol-associated liver disease. The Springer Nature webinar is free but you must have an account and be registered for this webinar. #livertwitter #alcohol #ALD
https://t.co/REPUQwcgMx
0
4
27
Very proud of you!
Delivered my first oral presentation at the VCU Cancer Research Conference. Grateful to my mentors @juanpabloarab @FcoIdalsoaga and my amazing colleagues @Ximena_Parraga_ @kavin_parmar @dami_gu @OmarAdnanA for all the support and encouragement. @VCU_Liver @VCUMassey
2
0
9
Join us for our next research seminar on Nov. 19 at noon. Our @ObiAseemMDPhD will speak on "Transcriptomic and Lipidomic Regulation of Cholangiocyte Fibroinflammatory Signaling in Biliary Fibrosis." Register at https://t.co/kttfOwcZqP
0
0
5
🎉 🎉to our #VCUHealth docs who won awards from the #AASLDFoundation for the recent #TLM2025 in DC. Sahaj Rathi and @butrosfakhoury won Early Career Investigator Awards and Rehan K. Razzaq was selected for the foundation’s Emerging Liver Scholars program.
3
5
24
New #TLM2025 data finds #cannabis use was linked to a lower 3️⃣-year risk of alcohol-associated #LiverDisease in #AlcoholUseDisorder patients. ❌ But don’t recommend cannabis for “liver protection” just yet, @juanpabloarab @VCU warned. #LiverTwitter
https://t.co/6gZrfJjlbE
healio.com
Cannabis use was associated with lower risk for alcohol-associated liver disease over 3 years among patients with alcohol use disorder, according to results of a large multi-institutional study...
0
3
6
Happy to see our work highlighted in the ALD debrief at #TLM25
@VCU_Liver #TLM2025
@AASLDtweets @AASLDPresident @AASLDFoundation @AmCollegeGastro @AmerGastroAssn @INASL_Liver @EASLedu @EASLnews
@juanpabloarab @butrosfakhoury @LuisAntonioDiaz
0
3
7